Literature DB >> 17521346

Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission.

Xiao-Feng Yang1, Aryan Weisenfeld, Steven M Rothman.   

Abstract

PURPOSE: The antiepileptic drug levetiracetam (LEV) is an enigma. Despite the fact that it specifically binds to the presynaptic vesicle protein, SV2A, no satisfactory mechanism of action has yet been identified. Using a combination of electrophysiological and cellular imaging techniques, we carefully tested the hypothesis that LEV directly interferes with neurotransmitter release.
METHODS: We measured extracellular evoked responses in the CA1 region of rat hippocampal slices after paired pulse stimulation and after application of up to 10 pulses applied at 5-80 Hz. In parallel experiments, we used quantitative 2-photon microscopy and the fluorescent vesicular marker FM1-43 to measure the effect of repetitive stimulation on presynaptic vesicle release.
RESULTS: Acute exposure to LEV (100 microM) had no effect on paired pulse synaptic responses. However, when slices were exposed to LEV for 3 h, there was a significant alteration in paired pulse responses and a more striking reduction in late synaptic potentials delivered in an 80 Hz train. LEV significantly reduced the rate of vesicle release assessed by FM1-43 destaining during 1 Hz stimulation.
CONCLUSION: LEV is unique among currently available antiepileptics, because it directly inhibits presynaptic neurotransmitter release in a use-dependent fashion. While there are alternate explanations for this observation, it is plausible that LEV exerts its effect by binding to a protein selectively expressed in presynaptic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17521346     DOI: 10.1111/j.1528-1167.2006.01132.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  36 in total

Review 1.  Spotlight on levetiracetam in epilepsy.

Authors:  Katherine A Lyseng-Williamson
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 2.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

4.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

5.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

6.  How ready can a synaptic vesicle be? SV2 may have the answer.

Authors:  Gregory C Mathews
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

7.  Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus.

Authors:  Chun-Yao Lee; Chih-Chuan Chen; Horng-Huei Liou
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 8.  Network abnormalities and interneuron dysfunction in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Rev Neurosci       Date:  2016-11-10       Impact factor: 34.870

9.  Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics.

Authors:  Cameron S Metcalf; Brian D Klein; Daniel R McDougle; Liuyin Zhang; Dan Kaufmann; Grzegorz Bulaj; H Steve White
Journal:  Epilepsia       Date:  2017-01-18       Impact factor: 5.864

10.  Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.

Authors:  V Daniels; M Wood; K Leclercq; R M Kaminski; M Gillard
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.